SOLID TUMORS (PHASE 1)
Clinical trials for SOLID TUMORS (PHASE 1) explained in plain language.
Never miss a new study
Get alerted when new SOLID TUMORS (PHASE 1) trials appear
Sign up with your email to follow new studies for SOLID TUMORS (PHASE 1), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill targets hard-to-treat cancers with BRAF mutation
Disease control Recruiting nowThis early-phase study tests an experimental oral drug, HSK42360-Na, in adults with advanced solid tumors that have a specific genetic change (BRAF V600 mutation) and have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and…
Matched conditions: SOLID TUMORS (PHASE 1)
Phase: PHASE1 • Sponsor: Haisco Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated May 17, 2026 03:42 UTC
-
New drug ADCE-B05 targets Hard-to-Treat cancers in first human trial
Disease control Recruiting nowThis early-phase study tests a new drug called ADCE-B05 in people with advanced solid tumors that have not responded to other treatments. The main goals are to find the safest dose and to check for side effects. About 180 adults will take part, and the drug is given alone at diff…
Matched conditions: SOLID TUMORS (PHASE 1)
Phase: PHASE1 • Sponsor: Adcendo ApS • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New drug targets Hard-to-Treat cancers with missing gene
Disease control Recruiting nowThis early-phase study tests a new oral drug, ABSK131, in adults with advanced solid tumors that have lost the MTAP gene. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors or slow their growth. About 266 participants will take the drug…
Matched conditions: SOLID TUMORS (PHASE 1)
Phase: PHASE1 • Sponsor: Abbisko Therapeutics Co, Ltd • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New pill targets Hard-to-Treat cancers with RAS mutations
Disease control Recruiting nowThis early-phase study tests a new daily pill, AN9025, in people with advanced solid tumors that have specific RAS gene mutations. The main goals are to check the drug's safety and find the right dose. About 91 adults will take the drug daily and visit the clinic regularly for mo…
Matched conditions: SOLID TUMORS (PHASE 1)
Phase: PHASE1 • Sponsor: Adlai Nortye Biopharma Co., Ltd. • Aim: Disease control
Last updated May 07, 2026 18:42 UTC